

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket Number 5405-232DV		Serial No. 09/384,749 972,714	
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)				Applicants: Amalfitano et al.			
Filing Date: Concurrently herewith				Group: Unknown			
U. S. PATENT DOCUMENTS							
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
R	1	5,399,346	03/21/95	Anderson et al.	424	93.21	
	2	5,518,913	05/21/96	Massie et al.	435	235.1	
	3	5,585,362	12/17/96	Wilson et al.	514	44	
	4	5,670,488	09/23/97	Gregory et al.	514	44	
	5	5,674,722	10/07/97	Mulligan et al.	435	172.3	
	6	5,700,470	12/23/97	Saito et al.	424	233.1	
	7	5,707,618	01/13/98	Armentano et al.	424	93.21	
	8	5,731,172	03/24/98	Saito et al.	435	91.42	
	9	5,824,544	10/20/98	Armentano et al.	435	320.1	
	10	5,837,511	11/17/98	Falck-Pedersen et al.	435	172.3	
	11	5,849,561	12/15/98	Falck-Pedersen	435	235.1	
	12	5,851,806	12/22/98	Kovesdi et al.	435	91.41	
	13	5,877,011	03/02/99	Armentano et al.	435	320.1	
	14	5,880,102	03/09/99	George et al.	514	44	
	15	5,882,877	03/16/99	Gregory et al.	435	320.1	
	16	5,891,690	04/06/99	Massie	435	172.3	
	17	5,891,715	04/06/99	Haddada et al.	435	320.1	
	18	5,919,676	07/06/99	Graham et al.	435	172.3	
	19	5,922,576	07/13/99	He et al.	435	91.41	
	20	5,928,944	07/27/99	Seth et al.	435	375	
	21	5,980,886	11/09/99	Kay et al.	424	93.21	
	22	5,981,225	11/09/99	Kochanek et al.	435	69.1	
	23	5,981,275	11/09/99	Armentano et al.	435	320.1	
	24	5,994,106	11/30/99	Kovesdi et al.	435	91.4	
	25	5,994,132	11/30/99	Chamberlain et al.	435	369	
	26	6,013,638	01/11/00	Crystal et al.	514	44	
	27	6,057,158	05/02/00	Chamberlain et al.	435	456	

EXAMINER
EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket Number 5405-232DV		Serial No. 09/384,749	
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)							
				Applicants: Amalfitano et al.			
				Filing Date: Concurrently herewith		Group: Unknown	
28	6,063,622	05/16/00	Chamberlain et al.	435	369	/	
29	6,083,750	07/04/00	Chamberlain et al.	435	369	/	
FOREIGN PATENT DOCUMENTS							
	Document Number	Date	Country	Class	Subclass	Translation Yes No	
30	WO 90/07573	07/12/90	WIPO	C12N	9/24		
31	WO 94/28152	12/08/94	WIPO	C12N	15/86		
32	WO 98/17783	04/30/98	WIPO	C12N	5/06		
33	WO 96/10088	04/04/96	WIPO	C12N	15/86	X (Abstract)	
34	712304	04/19/96	Australia	C12N	15/86	X	
35	WO 96/13597	05/09/96	WIPO	C12N	15/86	X	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
36	Amalfitano et al.: Modification of Adenoviral vectors for use in gene therapy of Duchenne Muscular Dystrophy, <i>The American Journal of Human Genetics</i> 57:4 Abstract #1354 Poster Symposium - Session 32 (1995)						
37	Amalfitano et al.: Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors, <i>Proc. Natl. Acad. Sci. USA</i> 93:3352-3356 (1996)						
38	Amalfitano et al.: Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy, <i>Gene Therapy</i> 4:258-263 (1997)						
39	Amalfitano et al.: A new class of adenovirus vector: the [E1-, E2b-]Ad vector, <i>Molecular and Cellular Biology of Gene Therapy</i> E:6 24 (1997)						
40	Amalfitano et al.: Production and Characterization of Improved Adenovirus Vectors with the E1, E2b, and E3 Genes Deleted, <i>Journal of Virology</i> 72:2 926-933 (1998)						
41	Amalfitano, Editorial, <i>Gene Therapy</i> 6:1643-1645 (1999)						
42	Amalfitano et al.: Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid- α -glucosidase, <i>Proc. Natl. Acad. Sci. USA</i> 96:8861-8866 (1999)						
44	Angeletti et al.: Adenovirus Preterminal Protein Binds to the CAD Enzyme at Active Sites of Viral DNA Replication on the Nuclear Matrix, <i>Journal Of Virology</i> 72:4 2896-2904 (1998)						
44	Armentano et al.: Effect of the E4 Region on the Persistence of Transgene Expression from Adenovirus Vectors, <i>Journal Of Virology</i> 71:3 2408-2416 (1997)						
40	Bett et al.: An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3, <i>Proc. Natl. Acad. Sci. USA</i> 91:8802-8806 (1994)						
46	Brough et al.: Activation of Transgene Expression by Early Region 4 Is Responsible for a High Level						

 EXAMINER
 EXAMINER

DATE CONSIDERED

6/11/03

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 5405-232DV	Serial No. 09/384,749
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Applicants: Amalfitano et al.	
		Filing Date: Concurrently herewith	Group: Unknown
		of Persistent Transgene Expression from Adenovirus Vectors <i>In Vivo</i> , <i>Journal Of Virology</i> 71:12 9206-9213 (1997)	
	47	Byrne et al.; Gene replacement in acid maltase deficiency using DNA viral vectors," <i>Pediatric Research</i> 41:19a XP000934188 (1997).	
	48	Caravokyri et al.: Constitutive Episomal Expression of Polypeptide IX (pIX) in a 293-Based Cell Line Complements the Deficiency of pIX Mutant Adenovirus Type 5, <i>Journal Of Virology</i> 69:11 6627-6633 (1995)	
	49	Cepko et al.: Analysis of Ad5 Hexon and 100K ts Mutants Using Conformation-Specific Monoclonal Antibodies, <i>Virology</i> 129 137-154 (1983)	
	50	Chamberlain et al.: Packaging cells expressing the Adenovirus (Ad) E1, polymerase, and preterminal proteins to allow the growth of a new class of replication defective Ad- vector for use in Duchenne muscular dystrophy (DMD), <i>The American Journal of Human Genetics</i> 59:4 Abstract #2196 (1996)	
	51	Clemens et al.: In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes, <i>Gene Therapy</i> 3 965-972 (1996)	
	52	Cox et al.: Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity, <i>Nature</i> 364:725-729 (1993)	
	53	Dedieu et al.: Long-Term Gene Delivery into the Livers of Immunocompetent Mice with E1/E4-Defective Adenoviruses, <i>Journal Of Virology</i> 71:6 4626-4637 (1997)	
	56	Douglas et al.: A system for the propagation of adenoviral vectors with genetically modified receptor specificities, <i>Nature Biotechnology</i> , 17 470-475 (1999)	
	56	Elferink et al.: Isolation and characterization of a precursor form of lysosomal α -glucosidase from human urine, <i>Eur. J. Biochem.</i> , 139, 489-495 (1984)	
	56	Gao et al.: Biology of adenovirus Vectors with E1 and E4 Deletions for Liver-Directed Gene Therapy, <i>Journal Of Virology</i> , 70:12 8934-8943 (1996)	
	57	Gilgenkrantz et al.: Transient Expression of Genes Transferred <i>In Vivo</i> into Heart Using First-Generation Adenoviral Vectors: Role of the Immune Response, <i>Human Gene Therapy</i> , 6, 1265-1274 (1995)	
	58	Goldman et al.: Transfer of the CFTR Gene to the Lung of Nonhuman Primates with E1-Deleted, E2a-Defective Recombinant Adenoviruses: A Preclinical Toxicology Study, <i>Human Gene Therapy</i> , 6, 839-851 (1995)	
	60	Gorziglia et al.: Generation of an Adenovirus Vector Lacking E1, E2a, E3, and All E4 except Open Reading Frame 3, <i>Journal Of Virology</i> , 73:7, 6048-6055 (1999)	
	60	Graham et al.: Characteristics of a Human cell Line Transformed by DNA from Human Adenovirus Type 5, <i>J. gen. Virol.</i> , 36, 59-72 (1977)	
	61	Guo et al.: Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer, <i>Gene Therapy</i> , 3, 802-810 (1996)	
	62	Guo et al.: Comparison of Viral Gene-Deleted Adenoviral Vectors With the E1-Deleted Adenoviral Vector in Islets, <i>Transplantation Proceedings</i> , 31, 794 (1999)	

EXAMINER
EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

6/1/03

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 5405-232DV	Serial No. 09/384,749
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Applicants: Amalfitano et al.	
		Filing Date: Concurrently herewith	Group: Unknown
<i>m</i>	63	Hardy et al.: Construction of Adenovirus Vectors through Cre-lox Recombination, <i>Journal Of Virology</i> , 71:3, 1842-1849 (1997)	
	64	Hartigan-O'Connor et al.: Increased Efficiency Of Gutted Adenovirus Production In Cells Expressing Preterminal Protein and DNA Polymerase, American Society of Gene Therapy <i>Adenoviruses</i> , Abstract #703 (1998)	
	65	Hartigan-O'Connor et al.: Improved Production of Gutted Adenovirus in Cells Expressing Adenovirus Preterminal Protein and DNA Polymerase, <i>Journal Of Virology</i> , 73:9, 7835-7841 (1999)	
	66	Hauser et al.: Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy, <i>Neuromuscular Disorders</i> 7, 277-283 (1997)	
	67	He et al.: A simplified system for generating recombinant adenoviruses, <i>Proc. Natl. Acad. Sci. USA</i> , 95, 2509-2514 (1998)	
	68	Hermans et al.: man lysosomal α -glucosidase: functional characterization of the cosylation sites, <i>M.J.</i> , 289, 681-686 (1993)	
	69	Hoefsloot et al.: Primary structure and processing of lysosomal α -glucosidase; homology with the intestinal sucrase – isomaltase complex, <i>The EMBO Journal</i> , 7:6, 1697-1704 (1988)	
	70	Hoefsloot et al.: Expression and routing of human lysosomal α -glucosidase in transiently transfected mammalian cells, <i>Biochem. J.</i> , 272 485-492 (1990)	
	71	Hu et al.: Persistence of an [E1 ⁻ , Polymerase ⁺] Adenovirus Vector Despite Transduction of a Neoantigen into Immune-Competent Mice, <i>Human Gene Therapy</i> 10, 355-364 (1999)	
	72	Ilan et al.: Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression, <i>Proc. Natl. Acad. Sci. USA</i> , 94, 2587-2592 (1997)	
	73	International Search Report; PCT/US99/19540.	
	71	Jones et al.: Isolation of Deletion and Substitution Mutants of Adenovirus Type 5, <i>Cell</i> , 13, 181-188 (1978)	
	73	Kaplan et al.: Characterization of Factors Involved in Modulating Persistence of Transgene Expression from Recombinant Adenovirus in the Mouse Lung, <i>Human Gene Therapy</i> , 8, 45-56 (1997)	
	76	Kochanek et al.: A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophic and β -galactosidase, <i>Proc. Natl. Acad. Sci. USA</i> , 93, 5731-5736 (1996)	
	73	Krougliak et al.: Development of Cell Lines Capable of Complementing E1, E4, and Protein IX Defective Adenovirus Type 5 Mutants, <i>Human Gene Therapy</i> , 6 1575-1586 (1995)	
	78	Kumar-Singh et al. "Encapsidated adenovirus minichromosomes as gene-delivery vehicles," <i>American Journal of Human Genetics</i> . 59:Suppl 4 page A202, ISSN: 0002-9297 (1996).	
<i>V</i>	79	Kumar-Singh et al.: Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells, <i>Human Molecular Genetics</i> 5:7, 913-921 (1996)	
	80	Kumar-Singh et al.: Encapsidated adenovirus mini-chromosome-mediated delivery of genes to the retina: application to the rescue of photoreceptor degeneration, <i>Human Molecular Genetics</i> 7:12,	

 EXAMINER
 EXAMINER

DATE CONSIDERED

6/7/03

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 5405-232DV	Serial No. 09/384,749
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Applicants: Amalfitano et al.	
		Filing Date: Concurrently herewith	Group: Unknown
		1893-1900 (1998)	
	81	Langer et al.: 293 Cell Lines That Inducibly Express High Levels of Adenovirus Type 5 Precursor Terminal Protein, <i>Virology</i> 221, 172-179 (1996)	
	82	Lieber et al.: Recombinant Adenoviruses with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Generation Vectors In Vitro and In Vivo, <i>Journal Of Virology</i> , 70:12, 8944-8960 (1996)	
	83	Lieber et al.: Adenoviral preterminal protein stabilizes mini-ade3noviral genomes in vitro and in vivo, <i>Nature Biotechnology</i> , 15 1383-1387 (1997)	
	84	Löser et al.; "Reactivation of the previously silenced cyromegalovirus major immediate-early promoter in the mouse liver: involvement of NfkappaB," <i>J. Virol.</i> 72:1 180-190 (January 1998).	
	85	Lusky et al.: In Vitro and In Vivo Biology of Recombinant Adenovirus Vectors with E1, E1/EW2A, or E1/E4 Deleted, <i>Journal Of Virology</i> , 72:3, 2023-2032 (1998)	
	89	Marienfeld et al.: 'Autoreplication' of the vector genome in recombinant adenoviral vectors with different E1 region deletions and transgenes, <i>Gene Therapy</i> 6, 1101-1113 (1999)	
	89	Martin-Touaux et al.; "In vivo gene therapy of Pompe disease using an adenoviral vector," <i>American Journal of Human Genetics</i> 65:A310 (October 1999).	
	88	Martiniuk et al.: Sequence of the cDNA and 5'-Flanking Region for Human Acid α -Glucosidase, Detection of an Intron in the 5' Untranslated Leader Sequence, Definition of 18-bp Polymorphisms, and Differences with Previous cDNA and Amino Acid Sequences, <i>DNA and Cell Biology</i> , 9:2, 85-94 (1990)	
	89	Martiniuk et al., Recombinant Human Acid α -Glucosidase Generated in Bacteria: Antigenic, but Enzymatically Inactive, <i>DNA and Cell Biology</i> 11:9 701-706 (1992)	
	90	Mathews; Control of Translation in Adenovirus-Infected Cells, <i>Enzyme</i> 44, 250-264 (1990)	
	91	Maxwell et al.: An Adenovirus Type 5 Mutant with the Preterminal Protein Gene Deleted Efficiently Provides Helper Functions for the Production of Recombinant Adeno-Associated Virus, <i>Journal Of Virology</i> , 72:10, 8371-8373 (1998)	
	92	McCoy et al, Nucleotide and Amino Acid Sequence Analysis of the 100K Protein of a Serotype 3 Porcine Adenovirus, <i>DNA Sequence: The Journal of Sequencing and Mapping</i> , 8:1-2, 59-61 (1997)	
	93	Mitani et al.: Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector, <i>Proc. Natl. Acad. Sci. USA</i> 92, 3854-3858 (1995)	
	84	Moorhead et al.: A Replication-Incompetent Adenovirus Vector with the Preterminal Protein Gene Deleted Efficiently Transduces Mouse Ears, <i>Journal Of Virology</i> , 73:2, 1046-1053 (1999)	
	95	Morin et al.: Hexon Trimerization Occurring in an Assembly-Defective, 100K Temperature-Sensitive Mutant of Adenovirus 2, <i>Virology</i> , 152, 11-31 (1986)	
	96	Morral et al.: Immune Responses to Reporter Proteins and High Viral Dose Limit Duration of Expression with Adenoviral Vectors: Comparison of E2a Wild Type and E2a Deleted Vectors, <i>Human Gene Therapy</i> , 8, 1275-1286 (1997)	

EXAMINER
EXAMINER

DATE CONSIDERED

6/9/03

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 5405-232DV	Serial No. 09/384,749
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Applicants: Amalfitano et al.	
		Filing Date: Concurrently herewith	Group: Unknown
97	Nakano et al.: Overproduction of adenovirus DNA polymerase and preterminal protein in HeLa cells, <i>Gene</i> 105, 173-178 (1991)		
98	Natarajan et al.; <i>Proximal and distal domains that control in vitro transcription of the adenovirus lva2 gene</i> , <i>Proc. Natl. Acad. Sci. USA</i> 81:6290-6294 (October 1984).		
99	Nevins; Mechanism of Activation of Early Viral Transcription by the Adenovirus E1A Gene Product, <i>Cell</i> 26 213-220 (1981)		
100	Nicolino et al.; "Adenovirus-mediated transfer of the acid alpha-glucosidase gene into fibroblasts, myoblasts and myotubes from patients with glycogen storage disease type II leads to high level expression of enzyme and corrects glycogen accumulation," <i>Hum Mol Genet.</i> 7:11 1695-1702 (October 1998).		
101	Niwa et al.: In vitro polyadenylation is stimulated by the presence of an upstream intron, <i>Genes & Development</i> , 1552-1559 (1990)		
102	Ohashi et al.: Adenovirus-mediated gene transfer and expression of human β -glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice, <i>Proc. Natl. Acad. Sci. USA</i> 94, 1287-1292 (1997)		
103	Oosterom-Dragon et al.: Purification and Preliminary Immunological Characterization of the Type 5 Adenovirus, Nonstructural 100,000-Dalton Protein, <i>Journal Of Virology</i> , 33:3, 1203-1207 (1980)		
104	Oosterom-Dragon et al.: Characterization of Two Temperature-Sensitive Mutants of Type 5 Adenovirus with Mutations in the 100,000-Dalton Protein Gene, <i>Journal Of Virology</i> , 40:2, 491-500 (1981)		
105	Parks et al.: A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal, <i>Proc. Natl. Acad. Sci. USA</i> , 93, 13565-13570 (1996)		
106	Pauly et al.: Complete correction of acid α -glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle, <i>Gene Therapy</i> , 5 473-470 (1998)		
107	Pettit et al.: Adenovirus Preterminal Protein Synthesized in COS Cells from Cloned DNA Is Active in DNA Replication In Vitro, <i>Journal Of Virology</i> , 62:2 496-500 (1988)		
108	Ragot et al.: Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice, <i>Nature</i> 361, 647-650 (1993)		
109	Ramachandra et al.: [10] Heterologous Expression, Purification, and Characterization of Adenovirus DNA Polymerase and Preterminal Protein, <i>Methods in Enzymology</i> 275 168-194 (1996)		
110	Raper et al.: Selective Gene Transfer into the Liver of Non-Human Primates with E1-Deleted, E2A-Defective, or E1-E4 Deleted Recombinant Adenoviruses, <i>Human Gene Therapy</i> 9, 671-679 (1998)		
111	Raper et al.: Developing adenoviral-mediated <i>in vivo</i> gene therapy for ornithine transcarbamylase deficiency, <i>J. Inher. Metab. Dis.</i> 21 (Suppl 1), 119-137 (1998)		
112	Reuser et al.: Uptake and Stability of Human and Bovine Acid α -Glucosidase in Cultured Fibroblasts and Skeletal Muscle Cells from Glycogenosis Type II Patients, <i>Experimental Cell Research</i> , 155, 178-189 (1984)		
113	Rich et al.: Development and Analysis of Recombinant Adenoviruses for Gene Therapy of Cystic		

EXAMINER
EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 5405-232DV	Serial No. 09/384,749
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)			
		Applicants: Amalfitano et al.	
		Filing Date: Concurrently herewith	Group: Unknown
		Fibrosis, <i>Human Gene Therapy</i> 4 461-476 (1993)	
	117	Riley et al.: RNA-Binding Properties of a Translational Activator, the Adenovirus L4 100-Kilodalton Protein, <i>Journal Of Virology</i> , 67:6, 3586-3595 (1993)	
	115	Rittner et al.: Conditional Repression of the E2 Transcription Unit in E1-E3-Deleted Adenovirus Vectors Is Correlated with a Strong Reduction in Viral DNA Replication and Late Gene Expression In Vitro, <i>Journal Of Virology</i> , 71:4, 3307-3311 (1997)	
	116	Scaria et al.: Complementation of a human adenovirus early region 4 deletion mutant in 293 cells using adenovirus-polylysine-DNA complexes, <i>Gene Therapy</i> , 2, 295-298 (1995)	
	117	Schaack et al.: Adenovirus terminal protein mediates both nuclear matrix association and efficient transcription of adenovirus DNA, <i>Genes & Development</i> 4, 1197-1208 (1990)	
	117	Schaack et al.: Adenovirus Type 5 Precursor Terminal Protein-Expressing 293 and HeLa Cell Lines, <i>Journal Of Virology</i> , 69:7, 4079-4085 (1995)	
	119	Schaack et al.: Characterization of a replication-incompetent adenovirus type 5 mutant deleted for the preterminal protein gene, <i>Proc. Natl. Acad. Sci. USA</i> 93, 14686-14691 (1996)	
	120	Slemenda et al.: Nucleotide sequence of the region coding for 100K and 33K proteins of human enteric adenovirus type 41 (Tak), <i>Nucleic Acids Research</i> 18:10, 3069 (1990)	
	120	Sudhanshu et al.: Sequence of Ovine Adenovirus Homologs for 100K Hexon Assembly, 33K, pVIII, and Fiber Genes: Early Region E3 Is Not in the Expected Location, <i>Virology</i> 209, 400-408 (1995)	
	122	Thomas et al.: DNA Replication and the Early to Late Transition in Adenovirus Infection, <i>Cell</i> 22 523-533 (1980) (Page 2)	
	123	Tribouley et al.: The Product of the Adenovirus Intermediate Gene IVa2 Is a Transcriptional Activator of the Major Lat Promoter, <i>Journal Of Virology</i> 68:7, 4450-4457 (1994)	
	124	Tripathy et al.: Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus, <i>Proc. Natl. Acad. Sci. USA</i> , 91, 11557-11561 (1994)	
	125	Tripathy et al.: Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors, <i>Nature Medicine</i> 2:5, 545-550 (1996)	
	126	Tsujino et al.: Adenovirus-Mediated Transfer of Human Acid Maltase Gene Reduces Glycogen Accumulation in Skeletal Muscle of Japanese Quail with Acid Maltase Deficiency, <i>Human Gene Therapy</i> , 9 1609-1616 (1998)	
	127	Van der Ploeg et al.: Prospect for enzyme therapy in glycogenosis II variants: a study on cultured muscle cells, <i>J. Neurol.</i> 235 392-396 (1988)	
	128	Van der Ploeg et al.: Intravenous Administration of Phosphorylated Acid α -Glucosidase Leads to Uptake of Enzyme in Heart and Skeletal Muscle of Mice, <i>J. Clin. Invest.</i> 87, 513-518 (1991)	
	129	Van Hove et al.: High-level production of recombinant human lysosomal acid α -glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease, <i>Proc. Natl. Acad. Sci. USA</i> , 93, 65-70 (1996)	

EXAMINER
EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 5405-232DV	Serial No. 09/384,749
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Applicants: Amalfitano et al.	
		Filing Date: Concurrently herewith	Group: Unknown
137	Vincent et al.: Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene, <i>nature genetics</i> 5, 130-134 (1993)		
131	Von Seggern et al.: A Helper-Independent Adenovirus Vector with E1, E3, and Fiber Deleted: Structure and Infectivity of Fiberless Particles, <i>Journal Of Virology</i> , 73:2, 1601-1608 (1999)		
132	Vrati et al.: Sequence of Ovine Adenovirus Homologs for 100K Hexon Assembly, 33K, pVIII, and Fiber Genes, Early Region E3 Is Not in the Expected Location, <i>Virology</i> 209:400-408 (1995).		
133	Wang et al.: A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions, <i>Gene Therapy</i> , 2, 775-783 (1995)		
134	Wang et al.: Persistent transgene expression in mouse liver following in vivo gene transfer with a $\Delta E1/\Delta E4$ adenovirus vector, <i>Gene Therapy</i> , 4, 393-400 (1997)		
135	Webster et al.: Domain Organization of the Adenovirus Preterminal Protein, <i>Journal Of Virology</i> , 71:1, 539-547 (1997)		
136	Webster et al.: Role of Preterminal Protein Processing in Adenovirus Replication, <i>Journal Of Virology</i> , 71:9, 6381-6389 (1997)		
137	Wisselaar et al.: Structural and Functional Changes of Lysosomal Acid α -Glucosidase during Intracellular Transport and Maturation, <i>The Journal Of Biological Chemistry</i> , 268:3, 2223-2231 (1993)		
138	Wolff et al.: Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle, <i>Human Molecular Genetics</i> , 1:6, 363-369 (1992)		
138	Yang et al.: Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy, <i>Proc. Natl. Acad. Sci. USA</i> , 91, 4407-4411 (1994)		
140	Yang et al.: Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis, <i>Nature Genetics</i> , 7, 362-369 (1994)		
141	Yang et al.: MHC Class I-Restricted Cytotoxic T Lymphocytes to Viral Antigens Destroy Hepatocytes in Mice Infected with E1-Deleted Recombinant Adenoviruses, <i>Immunity</i> 1 433-442 (1994)		
142	Yang et al; Cellular and Humoral Immune Responses to Viral Antigens Create Barriers to Lung-Directed Gene Therapy with Recombinant Adenoviruses, <i>Journal Of Virology</i> , 69:4, 2004-2015 (1995)		
143	Yang et al.: Clearance of Adenovirus-Infected Hepatocytes by MHC Class I-Restricted CD4 ⁺ CTLs In Vivo, <i>The Journal of Immunology</i> , 2564-2569 (1995)		
144	Yang et al.: Role of Viral Antigens in Destructive Cellular Immune Responses to Adenovirus Vector-Transduced Cells in Mouse Lungs, <i>Journal Of Virology</i> , 70:10, 7209-7212 (1996)		
145	Yeh et al.: Efficient Dual Transcomplementation of Adenovirus E1 and E4 Regions from a 293-Derived Cell Line Expressing a Minimal E4 Functional Unit, <i>Journal Of Virology</i> , 70:1, 559-565 (1996)		
146	Zhao et al.: Synthesis of biologically active adenovirus preterminal protein in insect cells using a baculovirus vector, <i>Gene</i> , 100 147-154 (1991)		
147	Zhou et al.: Development of a Complementing Cell Line and a System for Construction of Adenovirus Vectors with E1 and E2a Deleted, <i>Journal Of Virology</i> , 70:10, 7030-7038 (1996)		

 EXAMINER
 EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket Number
5405.232DV

Serial No.
09/972,794

LIST OF DOCUMENTS CITED BY APPLICANT

(Use several sheets if necessary)



Applicants:

Amalfitano et al.

Filing Date:

October 5, 2001

Group

1633

U. S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
<i>DR</i>	1.	6,066,626	05/23/00	Yew et al.	514	44	
	2.	6,019,978	02/01/00	Ertl et al.	424	199.1	
	3.	5,998,598	12/07/99	Csaky et al.	536	23.4	
	4.	5,998,205	12/0799	Hallenbeck et al.	435	325	
	.	5,354,678	10/11/94	Lebkowski et al.	435	172.3	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No
<i>DR</i>	5.	WO 98/13499	04/02/98	PCT	C12N	15/34	N/A

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>DR</i>	6.	Rosenberg, "The Immunotherapy of Solid Cancers Based on Cloning the genes Encoding Tumor-Rejection Antigens," <i>Annu. Rev. Med</i> 47: 481-491 (1996).					

RECEIVED

OCT 25 2002

TECH CENTER 1600/2900

EXAMINER
*EXAMINER

DATE CONSIDERED

6/9/03

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.